# Tamoxifen in Treating Women With High-Risk Breast Cancer

> **NCT00002542** · PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 672 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** CMF regimen
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** epirubicin hydrochloride
- **DRUG:** fluorouracil
- **DRUG:** methotrexate
- **DRUG:** tamoxifen citrate
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00002542
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-07-20
- **Primary completion:** 2007-03-07
- **Final completion:** 2011-01-11
- **Target enrollment:** 672 (ACTUAL)
- **Last updated:** 2020-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002542, "Tamoxifen in Treating Women With High-Risk Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00002542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*